CIK 0002023658
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-10 | Hyep Ivan Chief Financial Officer | Exercise or conversion 10b5-1 | +12,500 | $3.79 | $47K | 142,355 |
| 2026-08-10 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −12,500 | $27.97 | $350K | 129,855 |
| 2026-08-10 | Hyep Ivan Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −12,500 | 26,336 | ||
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Exercise or conversion 10b5-1 | +12,500 | $3.79 | $47K | 157,855 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −22,757 | $28.60 | $651K | 135,098 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −4,413 | $29.82 | $132K | 130,685 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −830 | $30.31 | $25K | 129,855 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −11,592 | 58,992 | ||
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −908 | 38,836 | ||
| 2026-05-21 | Hyep Ivan Chief Financial Officer | Exercise or conversion 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
| 2026-05-21 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $20.42 | $188K | 145,355 |
| 2026-05-21 | Hyep Ivan Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −9,200 | 70,584 | ||
| 2026-04-21 | Hyep Ivan Chief Financial Officer | Exercise or conversion 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
| 2026-04-21 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $23.00 | $212K | 145,355 |
| 2026-04-21 | Hyep Ivan Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −9,200 | 39,744 | ||
| 2026-03-23 | Hyep Ivan Chief Financial Officer | Exercise or conversion 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
| 2026-03-23 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $18.52 | $170K | 145,355 |
| 2026-03-23 | Hyep Ivan Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −9,200 | 48,944 | ||
| 2026-03-04 | Hyep Ivan Chief Financial Officer | Exercise or conversion 10b5-1 | +2,963 | $3.79 | $11K | 148,318 |
| 2026-03-04 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −2,963 | $18.25 | $54K | 145,355 |
Page 1 of 3 · 51 trades